Company Performance Metrics
- Claudia Chavez-Munoz, M.D. PhD.: Chief Scientific Officer, Founder
- Jean-Romain Falconnet: Head of Business Development & LicensingPast Role: Galderma, VP, Corporate Development - Head of Transactions
About Conexeu Sciences Inc.
Conexeu Sciences is a biotechnology company advancing regenerative medicine with its patented collagen flowable gel platform. Emerging from over a decade of University research, Conexeu is developing this groundbreaking technology that could transform wound care, medical aesthetics, and tissue engineering. The company
holds patents in the U.S., E.U., Japan, Australia, and pending in Canada, underscoring its global leadership in this innovation.
At the forefront of Conexeu's portfolio is Ten Minute Tissue™, a liquid dermal extracellular matrix (ECM) that remains fluid at room temperature and transitions into a gel at body temperature (~37°C). This unique thermosensitive scaffold promotes cell migration, proliferation, differentiation and new tissue formation, enabling seamless integration into host tissue. Clinically proven in pilot studies, Ten Minute Tissue™ accelerates wound healing compared to market leaders, while reducing inflammation and supporting rapid, non-fibrotic healing, reducing the risk of scarring. With its innovative collagen IP platform, Conexeu has the potential to bridge the gap between dermal fillers, biostimulators, and tissue repair, offering a category-defining opportunity in the multi-billion-dollar aesthetics and tissue engineering markets.
Ten-Minute Tissue™ is an investigational product and has not been cleared or approved by any regulatory authority. For more information, visit www.conexeu.com.